API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/qsymia-phentermine-topiramate-drug-insights-and-market-forecasts-to-2032-301712347.html
https://endpts.com/icer-reaffirms-qsymia-as-most-cost-effective-obesity-treatment-in-final-report/
https://www.fiercebiotech.com/research/fighting-obesity-by-attacking-both-food-intake-and-energy-burn?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/marketing/prescription-drug-police-ding-vivus-for-misleading-qsymia-obesity-treatment-webpage
https://www.raps.org/news-and-articles/news-articles/2019/5/opdp-issues-second-untitled-letter-of-2019
https://www.forbes.com/sites/joshuacohen/2018/09/10/belviq-study-results-may-improve-the-fortunes-of-weight-loss-drugs/#2cefd3836a40
https://endpts.com/a-new-avenue-for-diet-pill-makers-uc-san-diego-researchers-uncover-root-of-leptin-resistance/
https://endpts.com/with-debt-looming-browbeaten-diet-pill-maker-orexigen-goes-bankrupt/
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-September-20-2017-1505884449.pdf
http://cphi-online.com/future-obesity-drugs-must-provide-improved-news038407.html
http://www.fiercepharma.com/story/vivus-counts-25m-q3-sales-300m-debt-how-can-it-possibly-cover-200m-plus-qsy/2015-11-05
http://www.fiercepharma.com/story/icahn-casts-his-eye-vivus-tender-offer-convertible-notes/2015-09-09
http://www.fiercepharmamarketing.com/story/brutal-honesty-drug-marketing-obesity-meds-its-key-avoiding-magic-pill-trap/2015-06-08
http://www.fiercepharma.com/story/eisai-predicts-long-awaited-operating-profit-rise-fiscal-2015/2015-05-15
http://pharmaceuticals.einnews.com/pr_news/260316327/vivus-files-lawsuit-against-teva-for-infringement-of-qsymia-patents
http://www.wsj.com/articles/weight-loss-drugs-seek-acceptance-from-patients-and-physicians-1426526252
http://www.fiercepharmamarketing.com/story/surprise-obesity-med-contrave-might-help-cv-outcomes-too-bad-orexigen-blabb/2015-03-04
http://www.fiercepharma.com/story/novo-nordisk-puts-500-saxenda-reps-us-streets-aiming-1b-weight-loss-sales/2015-01-26